Screener
Regenxbio RGNX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 21,616 | 19,883 | 42,922 | 40,230 |
| Other operating expenses | 12 | 45 | 48 | 60 |
| Total operating expenses | 78,756 | 84,637 | 168,511 | 161,522 |
| Income (loss) from operations | 29,263 | (63,278) | (54,099) | (51,151) |
| Other Income (Expense) | ||||
| Interest income from licensing | 17 | 21 | 33 | 46 |
| Investment income | 1,222 | 3,379 | 3,225 | 5,880 |
| Interest expense | (7,793) | (10,993) | (16,501) | (19,563) |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's operating income?
- Regenxbio (RGNX) reported operating income of $29.26M in Q2 2026.
- How has Regenxbio's operating income changed year-over-year?
- Regenxbio's operating income increased by 146.2% year-over-year, from -$63.28M to $29.26M.
- What is the long-term trend for Regenxbio's operating income?
- Over 4 years (2021 to 2025), Regenxbio's operating income has grown at a 0.2% compound annual growth rate (CAGR), from $159.98M to -$161.2M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Regenxbio's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude